Tetra Tech Awarded £36 Million Multiple-Award Contract for Water Infrastructure Services
Tetra Tech, Inc. (NASDAQ: TTEK), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today that Severn Trent Water has selected Tetra Tech for a £36 million multiple-award contract to provide comprehensive water infrastructure services in the United Kingdom.
Under the 3-year contract, Tetra Tech engineers will conduct geotechnical investigations to assess soil and groundwater conditions to support the development of Severn Trent Water's capital improvements projects. Tetra Tech technical specialists will capture data in the field using cloud-based software to optimize data collection, validate data at the source, and synchronize collection efforts across field teams.
'Tetra Tech uses its innovative Leading with Science ® approach across all phases of the water cycle to design solutions that protect our global water supplies,' said Dan Batrack, Tetra Tech Chairman and CEO. 'We look forward to supporting Severn Trent Water to develop resilient water supplies for its millions of customers now and into the future.'
About Tetra Tech
Tetra Tech is the leader in water, environment and sustainable infrastructure, providing high-end consulting and engineering services for projects worldwide. With 30,000 employees working together, Tetra Tech provides clear solutions to complex problems by Leading with Science ® to address the entire water cycle, protect and restore the environment, design sustainable and resilient infrastructure, and support the clean energy transition. For more information about Tetra Tech, please visit tetratech.com or follow us on LinkedIn and Facebook.
Any statements made in this release that are not based on historical fact are forward-looking statements. Any forward-looking statements made in this release represent management's best judgment as to what may occur in the future. However, Tetra Tech's actual outcome and results are not guaranteed and are subject to certain risks, uncertainties and assumptions ("Future Factors"), and may differ materially from what is expressed. For a description of Future Factors that could cause actual results to differ materially from such forward-looking statements, see the discussion under the section "Risk Factors" included in the Company's Form 10-K and Form 10-Q filings with the Securities and Exchange Commission.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
3 hours ago
- Cision Canada
AI in Healthcare Just Crossed a Tipping Point. Investors Are Watching These Names
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 4, 2025 /CNW/ -- Equity Insider News Commentary – Generative AI is transforming healthcare faster than almost any other sector, according to a new McKinsey report. In a March survey of senior leaders across payers, providers, and healthcare services groups, 85% said they're actively using or exploring the technology. McKinsey's Global Institute estimates Gen AI could unlock $60–110 billion in annual value across pharma and medical products alone. With more AI pilot programs running than ever before, the tech world is racing to meet demand — including new efforts from Avant Technologies, Inc. (OTCQB: AVAI), Medtronic plc (NYSE: MDT), Butterfly Network, Inc. (NYSE: BFLY), Oracle Corporation (NYSE: ORCL), and Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Investor capital is pouring into AI-driven healthcare, with Pittsburgh-based Abridge AI Inc. pulling in $300 million at a $5.3 billion valuation. While several private players are making headlines, public markets are also heating up. Statista now projects the global AI healthcare market will soar from $11 billion to $188 billion by 2030 — a staggering 37% compound annual growth rate. Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is entering the final prototyping stage of a proprietary, automated retinal imaging device — marking a potential turning point in the companies' shared push toward AI-powered early diagnostics. The new device is designed to operate hands-free and feed imaging data directly into the Vision AI platform, enabling near-instant risk reports without expensive equipment or trained personnel. The companies say the camera, developed under their joint venture Ai-nova Acquisition Corp. (AAC), is expected to cost a fraction of legacy fundus cameras. By combining affordability with automation, the device could expand screening access across primary care clinics and emerging-market providers that have traditionally been priced out of ophthalmic diagnostics. "The cost of a fundus camera has always been a barrier to entry in this market," said Vinicio Vargas, CEO at Ainnova and board member of AAC. "Our low-cost camera, which is a fraction of the cost of currently available cameras on the market, should allow us to not only enter the market, but to capture a large share of the market." But hardware is only half the story. The new camera is being built to integrate seamlessly with Vision AI, Ainnova's diagnostic platform that uses retinal imaging, vital signs, and basic lab inputs to assess risk for a range of diseases. Already in use across clinical sites in Latin America, Vision AI currently supports risk scoring for diabetic retinopathy, glaucoma, age-related macular degeneration, cardiovascular disease, type 2 diabetes, liver fibrosis, and chronic kidney disease. "Another significant advantage will be that our camera will be seamlessly packaged together with our Vision AI platform, allowing us to refer more patients in less time and accurately to medical specialists," added Vargas. "Also, one of our objectives is to integrate other technologies to this preventive screening, expanding the scope from only diabetic patients to patients who have other risk factors and want to prevent other diseases from a more complete approach." The development comes at a critical time for Avant, which is in active talks to acquire Ainnova outright — a move that would consolidate leadership, simplify operations, and unify the companies under one roof ahead of a planned FDA pre-submission meeting scheduled for next month. The two companies already operate jointly through AAC, which holds global licensing rights to Ainnova's technology portfolio and serves as the commercialization engine for Vision AI and all future device deployments. While Vision AI remains compatible with third-party imaging equipment, the decision to design proprietary hardware marks a strategic shift toward product exclusivity — giving Avant greater control over the end-to-end user experience and enhancing its defensibility in a competitive early diagnostics landscape. Also in development are additional platform modules, including a patented dementia detection tool that combines a five-minute blood test with AI-trained algorithms. Although that technology remains in evaluation, the core platform continues to expand its reach and functionality — evolving from a retinal-focused application into a broader engine for predictive healthcare. "Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vargas in a previous statement. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions." As the camera prototype nears completion, Avant is positioning itself for broader market entry. While a launch date has yet to be announced, the integrated platform is designed to reduce diagnostic friction, speed up referrals, and expand access to early-stage health insights — especially in geographies where affordability, not innovation, remains the primary barrier to care. With hardware now entering the pipeline, software validated in clinical settings, and corporate consolidation on the table, Avant is no longer just building an AI model — it's building a diagnostic system. Medtronic plc (NYSE: MDT) capped off its fiscal year with strong Q4 results, reporting $8.9 billion in revenue and double-digit earnings growth. "We had a strong close to our fiscal year, and I'm excited to see the progress we are making as our growth drivers continue to build momentum," said Geoff Martha, Chairman and CEO of Medtronic. "The underlying fundamentals of our business are strong, and they are getting stronger." The company highlighted progress across growth franchises, including the launch of BrainSense™ Adaptive Deep Brain Stimulation (aDBS) — its largest-ever commercial rollout of brain-computer interface technology, a milestone in precision neuromodulation. Additionally, Medtronic's AiBLE™ spine surgery ecosystem and connected insulin delivery platforms further signal its growing focus on AI-integrated healthcare solutions. Butterfly Network, Inc. (NYSE: BFLY) kicked off 2025 with strong execution, growing Q1 revenue 20% year-over-year to $21.2 million and narrowing its net loss to $14 million. "2025 is off to a great start. The Butterfly team hit the mark again, delivering right on target with a 20% growth quarter," said Joseph DeVivo, President, CEOah and Chairman of Butterfly Network. "We're very proud of how the Company continues to mature." The company advanced its Butterfly HomeCare pilot program and added two new AI developers to its Butterfly Garden, while existing partner DESKi secured FDA clearance for its AI-driven HeartFocus cardiac app. Its portable iQ3 ultrasound device continued gaining traction, featured on HBO Max's The Pitt and adopted by major U.S. med schools. With a strengthened balance sheet and increasing AI integration, Butterfly reiterated guidance for $96–100 million in 2025 revenue. Oracle Corporation (NYSE: ORCL), through its subsidiary Oracle Health, in partnership with Cleveland Clinic and G42, has announced a strategic collaboration to develop a global AI-powered healthcare delivery platform. The initiative will combine Oracle's cloud and AI infrastructure with Cleveland Clinic's clinical expertise and G42's advanced AI models to deliver scalable, secure, and affordable care. "Aging populations, rising costs, and the complexity of care demand a complete reinvention of how healthcare is provided," said Larry Ellison, Executive Chairman and CTO of Oracle. " Oracle's AI Data Platform and suite of clinical applications can help us understand disease and population health in ways that fuel scientific breakthroughs, reduce the cost of care delivery, and improve patient care. Together with Cleveland Clinic and G42, we will deliver the modern tools providers need to help people live longer, healthier lives." Designed to support precision medicine and real-time clinical intelligence, the platform aims to improve outcomes while reducing costs across the U.S., UAE, and beyond. Recursion Pharmaceuticcals, Inc. (NASDAQ: RXRX) announced early Phase 2 results from its TUPELO trial evaluating REC-4881 in patients with Familial Adenomatous Polyposis (FAP), a rare genetic disorder with no approved therapies. "For patients with FAP, who currently lack FDA-approved treatment options, Recursion's AI-powered Recursion OS platform identified a promising approach through MEK 1/2 inhibition," said Najat Khan, PhD, Chief R&D Officer and Chief Commercial Officer at Recursion. "By analyzing cellular models of APC gene loss, we uncovered a potential first-in-disease treatment and are excited to share our preliminary findings." The AI-discovered MEK1/2 inhibitor reduced polyp burden by a median of 43% in just 13 weeks among evaluable patients, with 83% showing clinical response. The study also reported improvements in upper GI disease severity and a manageable safety profile consistent with known MEK inhibitors. REC-4881 was developed through Recursion's in-house AI platform, Recursion OS, which analyzed APC gene loss models to generate a novel treatment pathway. CONTACT: Equity Insider [email protected] (604) 265-2873 DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
Cision Canada
9 hours ago
- Cision Canada
Perimeter Launches OCT-Tissue Registry to Power AI and Imaging Innovation
TORONTO and DALLAS, June 4, 2025 /CNW/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTCQX: PYNKF) (" Perimeter" or the " Company") announced today that it has launched the OCT-Tissue Surveillance Registry, a database that aims to collect thousands of images and data from surgical procedures performed using the company's imaging technology. Perimeter will use the registry to inform future product development and continually enhance the artificial intelligence ("AI") deep-learning model for its investigational next-generation technology. "I have used Perimeter's OCT technology in more than 120 surgeries, and it has become an invaluable tool," said Dr. Jennifer Tittensor, a general surgeon for Timpanogos Regional Hospital and the first contributor to the OCT-Tissue Registry. "In my practice, it helps me assess margins in real-time and decide whether I need to remove more tissue - potentially avoiding the need for a second surgery. Being a part of the registry allows me to track and analyze patient outcomes and help shape future improvements in the technology. I am excited to be involved." Perimeter's S-Series OCT utilizes the company's patented wide-field optical coherence tomography ("OCT") technology to enable surgeons to visualize tissue specimens in real-time, with ultra-high resolution, during surgery. Building on this foundation, the investigational next-generation B-Series OCT with ImgAssist AI 2.0, under premarket approval review by the U.S. Food and Drug Administration, integrates AI and is intended to help surgeons more efficiently detect suspicious tissue during breast-conserving surgery. "The launch of this registry provides an opportunity to patients and surgeons to help future patients have better clinical care," said Perimeter CEO Adrian Mendes. "We look forward to collaborating with physicians to collect high-quality data and images from a broad and diverse patient population. The more images we can gather from the widest range of patients, the better we can train our AI algorithm to detect patterns in various tissue types. This registry could potentially help physicians provide more personalized care, achieve clean margins more frequently, and reduce the need for second surgeries due to residual cancer." One of the biggest challenges with developing non-generative AI for medical applications is acquiring a large, diverse dataset that reflects a full range of patient characteristics, such as age, ethnicity, tissue density, and body mass. To develop the ImgAssist AI algorithm, Perimeter trained its deep learning models using several million proprietary OCT images of cancerous and healthy tissue. These models, created by the company's AI team, were designed for real-time use. The launch of the OCT-Tissue Registry enables Perimeter to use real-world images and clinical data to make its AI model even more sophisticated. The registry also allows surgeons to contribute retrospective data and track patient outcomes to evaluate surgical results over time. To learn more or inquire about participation in OCT-Tissue Registry, please contact Perimeter Medical Imaging AI Clinical Affairs at [email protected]. About Perimeter Medical Imaging AI, Inc. Based in Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI (TSXV: PINK) (OTCQX: PYNKF) is a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address areas of high unmet medical need. Available across the U.S., our FDA-cleared Perimeter S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level. The breakthrough-device-designated investigational Perimeter B-Series OCT with ImgAssist AI represents our next-generation artificial intelligence technology that was evaluated in a pivotal clinical trial, with support from a grant of up to US$7.4 million awarded by the Cancer Prevention and Research Institute of Texas. Patient enrollment completed in September 2024, with expected FDA submission in 2025. The company's ticker symbol "PINK" is a reference to the pink ribbons used during Breast Cancer Awareness Month. S-Series Intended Use The S-Series OCT is indicated for use as an imaging tool in the evaluation of excised human tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization, with image review manipulation software for identifying and annotating regions of interest. S-Series Unapproved Uses The S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. Clinical evidence related to these uses can be found in the clinical evidence listed below. Contraindications, limitations, warnings and precautions, and how to obtain a full copy of the FDA-required instructions for use are also provided on this page. For more information on unapproved/off-label uses, contact [email protected]. B-Series Intended Use B-Series OCT is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer aided detection algorithm which identifies and marks focal areas suspicious for breast cancer and is used concurrently with physician interpretation of the images. The device is intended for use in conjunction with other standard methods for evaluation of the margins of an excised lumpectomy specimen during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer. CAUTION: Perimeter B-Series OCT is limited by U.S. law to investigational use and not available for sale in the United States. The safety and effectiveness of this device has not yet been evaluated by the U.S. FDA. For more information, please contact [email protected]. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. In this news release, words such as "may," "would," "could," "will," "likely," "believe," "expect," "anticipate," "intend," "plan," "estimate," and similar words and the negative form thereof are used to identify forward-looking statements. Forward-looking information may relate to management's future outlook and anticipated events or results and may include statements or information regarding the future financial position, business strategy and strategic goals, competitive conditions, research and development activities, projected costs and capital expenditures, research and clinical testing outcomes, taxes and plans and objectives of, or involving, Perimeter. Without limitation, information regarding the potential benefits of Perimeter S-Series OCT and Perimeter B-Series OCT, the expected benefits of Perimeter's updated version of its ImgAssist AI, and Perimeter's expectations regarding the PMA submission to the FDA are forward-looking information. Forward-looking statements should not be read as guarantees of future performance or results, and will not necessarily be accurate indications of whether, or the times at or by which, any particular result will be achieved. No assurance can be given that any events anticipated by the forward-looking information will transpire or occur. Forward-looking information is based on information available at the time and/or management's good-faith belief with respect to future events and are subject to known or unknown risks, uncertainties, assumptions, and other unpredictable factors, many of which are beyond Perimeter's control. Such forward-looking statements reflect Perimeter's current view with respect to future events, but are inherently subject to significant medical, scientific, business, economic, competitive, political, and social uncertainties and contingencies. In making forward-looking statements, Perimeter may make various material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include, but are not limited to, those applicable to Perimeter and described in Perimeter's Management Discussion and Analysis for the year ended December 31, 2023, which is available on Perimeter's SEDAR+ profile at and could cause actual events or results to differ materially from those projected in any forward-looking statements. Perimeter does not intend, nor does Perimeter undertake any obligation, to update or revise any forward-looking information contained in this news release to reflect subsequent information, events, or circumstances or otherwise, except if required by applicable laws. Stephen Kilmer Investor Relations Direct: 647-872-4849 Email: [email protected] Susan Thomas Media Relations Direct: 619-540-9195 Email: [email protected] Adrian Mendes Chief Executive Officer Toll-free: 888-988-7465 (PINK) Email: [email protected] SOURCE Perimeter Medical Imaging AI Inc.
Winnipeg Free Press
11 hours ago
- Winnipeg Free Press
Part toy, part fashion, the arrival of the viral Labubu was a long time in the making
Labubu, the plush toy from China's Pop Mart is a social media darling, but the toothy little monsters are far from an overnight success. Having appeared a decade ago, Labubus may have finally cemented their place in the collectible toy market for years to come. The Labubu, by artist and illustrator Kasing Lung, first appeared with pointed ears and pointy teeth, in three picture books inspired by Nordic mythology in 2015. In 2019 Lung struck a deal with Pop Mart, a company that caters to toy connoisseurs and influencers, to sell Labubu figurines. But it wasn't until Pop Mart started selling Labubu plush toys on key rings in 2023 that the toothy monsters suddenly seemed to be everywhere, including in the hands of Rihanna, Kim Kardashian and NBA star Dillon Brooks. K-pop singer Lisa of Blackpink began posting images of hers for her more than 100 million followers on Instagram and on TikTok, where Labubu pandemonium has broken out. There are 1.4 million #Labubu TikTok posts and counting, videos of fans unboxing them, showing styles inspired by them, and of course, Labubu cosplay. Fans have latched on to Labubu's mashup of play and fashion, making them accessories on handbags, backpacks and belts, or hanging them from car mirrors. 'The character has evolved into a collectible and style symbol, resonating with fans who connect with its quirky aesthetic and unique backstory,' Emily Brough, Popmart's head of IP licensing in the Americas, said. Labubu has been a bonanza for Pop Mart. Its revenue more than doubled in 2024 to 13.04 billion yuan ($1.81 billion), thanks in part to its elvish monster. Revenue from Pop Mart's plush toys soared more than 1,200% in 2024, nearly 22% of its overall revenue, according to the company's annual report. Aside from their ability to pique the interest of toy aficionados and fashionistas, Labubu latched on to the blind box phenomenon, where the purchaser doesn't know exactly which version of the plush toy they'll get. And Pop Mart made sure there is a Labubu for everyone, regardless of income. Most are priced in a wide rage between $20 and $300, with certain collaborations or limited editions priced higher, according to Brough. Unlike many toys, Labubu devotees include a large number of adults. Buyers ages 18 and over drove a year-over-year increase of more than $800 million in the U.S. toy market in 2024, according to market research firm Circana. Adult shoppers, mostly female, bought the toys for themselves. In 2025's first quarter, toy sales for those ages 18 and over rose 12% from the prior-year period. At $1.8 billion, adults also accounted for the highest spending among all age groups in the quarter. Like many retailers, Pop Mart is actively monitoring negotiations between the U.S. and just about every one of its trading partners as prices may be impacted. The situation with China is at the forefront, with President Donald Trump saying on Friday that the country 'violated' an agreement with the United States on trade talks. Right now Pop Mart, whose products are manufactured across Asia, says that it is continuously scaling production and expanding distribution across its online shop, retail stores and blind box vending machines to meet increasing demand. Monday Mornings The latest local business news and a lookahead to the coming week. Short supply has led to long lines at stores and at least one physical fight at a shopping center in the United Kingdom. Pop Mart said in an Instagram post late last month that it was temporarily suspending all in-store and blind box machine sales in the U.K. Peter Shipman, head of Europe, said in a Facebook post that the company is currently working on a new method to distribute toys to stores. Resellers have become problematic and many Labubu fans are still willing to pay exorbitant price markups. Kena Flynn was at The Grove shopping center in Los Angeles recently when she stumbled upon some Labubus being sold at a kiosk. Flynn said in a TikTok on Sunday that the prices were 'really bad,' but her boyfriend bought two anyway. 'At a certain point, you can't buy them,' Flynn said in her video. 'I just want a Labubu and I cannot buy one from Pop Mart, so here we are.' Looking to keep up with the overwhelming demand, Pop Mart says it's on track for 50 more retail locations in the U.S. by the end of the year. That'll give shoppers more chances to hunt for Labubus, as Pop Mart says it's planning multiple new Labubu releases tied to seasonal moments and holidays throughout the rest of the year.
